Cantor Fitzgerald Comments on Zai Lab FY2025 Earnings

Zai Lab Limited (NASDAQ:ZLABFree Report) – Stock analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of Zai Lab in a research report issued on Tuesday, January 21st. Cantor Fitzgerald analyst L. Chen forecasts that the company will post earnings of ($1.38) per share for the year. Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Zai Lab’s current full-year earnings is ($2.58) per share.

Separately, JPMorgan Chase & Co. boosted their price target on shares of Zai Lab from $38.00 to $44.00 and gave the stock an “overweight” rating in a report on Monday, October 21st.

Get Our Latest Stock Analysis on Zai Lab

Zai Lab Trading Up 2.4 %

Shares of ZLAB opened at $26.63 on Wednesday. The firm has a market cap of $2.91 billion, a P/E ratio of -9.61 and a beta of 1.00. Zai Lab has a 12 month low of $13.48 and a 12 month high of $36.60. The stock’s 50 day moving average is $26.59 and its two-hundred day moving average is $23.76.

Institutional Investors Weigh In On Zai Lab

A number of hedge funds have recently modified their holdings of ZLAB. Janus Henderson Group PLC boosted its holdings in Zai Lab by 34.2% in the 3rd quarter. Janus Henderson Group PLC now owns 8,760,074 shares of the company’s stock valued at $211,488,000 after purchasing an additional 2,232,507 shares during the last quarter. Wellington Management Group LLP raised its position in shares of Zai Lab by 18.4% during the 3rd quarter. Wellington Management Group LLP now owns 8,436,606 shares of the company’s stock valued at $203,660,000 after buying an additional 1,312,115 shares during the period. Connor Clark & Lunn Investment Management Ltd. lifted its holdings in Zai Lab by 26.2% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 604,153 shares of the company’s stock valued at $14,584,000 after acquiring an additional 125,532 shares during the last quarter. Bamco Inc. NY grew its position in Zai Lab by 6.4% in the third quarter. Bamco Inc. NY now owns 1,906,520 shares of the company’s stock worth $46,023,000 after acquiring an additional 113,869 shares during the period. Finally, Algert Global LLC acquired a new stake in Zai Lab during the third quarter worth $1,666,000. Hedge funds and other institutional investors own 41.65% of the company’s stock.

Insider Buying and Selling at Zai Lab

In related news, insider Rafael Amado sold 7,583 shares of the company’s stock in a transaction dated Tuesday, December 31st. The shares were sold at an average price of $26.28, for a total transaction of $199,281.24. Following the completion of the sale, the insider now owns 33,834 shares of the company’s stock, valued at approximately $889,157.52. This represents a 18.31 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 13.88% of the stock is currently owned by insiders.

About Zai Lab

(Get Free Report)

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.

Further Reading

Receive News & Ratings for Zai Lab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zai Lab and related companies with MarketBeat.com's FREE daily email newsletter.